Caladrius (CLBS) the former NeoStem engages in the development of proprietary cell therapy products.
Caladrius Biosciences, Inc. is a clinical stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications.
CLBS is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in an ongoing Phase 2 trial.
CLBS14, a CD34+ cell therapy intended as a treatment for coronary microvascular dysfunction, is Caladrius’ proprietary and patent protected formulation of CD34 cells designed specifically to enhance the potency of the CD34 cells for repair and regeneration of cardiovascular tissue. Its companion product, CLBS12, is specifically formulated for intramuscular administration for the treatment of lower extremity ischemia.
A phase 2 study of CLBS12 as a treatment for critical limb ischemia recently was initiated in Japan, a successful outcome of which will qualify the program for consideration of early conditional approval based on discussions with the Japanese regulatory authorities as provided for under Japan’s progressive regenerative medicine regulations.
Founded as NeoStem in 1980, CLBS is headquartered in Basking Ridge, NJ.
March 21, 2022
RegMed Investors’ (RMi) closing bell: sector highs respond to lessened resistance motivating sentiment
March 21, 2022
RegMed Investors’ (RMi) pre-open: holding onto gains or evacuate from risk
March 21, 2022
RegMed Investors’ (RMi) pre-open: holding onto gains or evacuate from risk
March 17, 2022
RegMed Investors’ (RMi) closing bell: Algorithmic tailwinds are pushing the cell and gene therapy sector upward
March 16, 2022
RegMed Investors’ (RMi) pre-open: the “always” question, what’s sustainable
March 15, 2022
RegMed Investors’ (RMi) closing bell: it’s about time for the oversold cell and gene therapy sector logjam to come back to appreciation
March 10, 2022
RegMed Investors’ (RMi) closing bell: the algorithms beat me to the profit window
March 3, 2022
RegMed Investors’ (RMi) closing bell: a worried sector, downtrodden by war anxieties
February 24, 2022
RegMed Investors’ (RMi) closing bell: a lot of buys on first day of a disclosed Ukraine attack
35 companies, 1 interpreter!
Insight, foresight and recommendation
Caladrius (CLBS) -- Started 2018 at $3.70, saw a high of $4.30 dropped on February 1 to $4.12 and has been dribbling between 2/7 to 2/16 at $3.93. 3/6 – a surprise, Caladrius Biosciences (CLBS) acquired an exclusive license to a late stage CD34+ Cell Therapy Program for the treatment of Refractory Angina from Shire plc (SHP.L) (SHPG). CLBS had closed at $5.03 and was up +$1.58 slipping to $0.55 or +11.13% (was +31.41%) …
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors